nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—Red blood cell sedimentation rate increased—Ezetimibe—atherosclerosis	0.0243	0.0526	CcSEcCtD
Methysergide—Red blood cell sedimentation rate increased—Simvastatin—atherosclerosis	0.0232	0.0502	CcSEcCtD
Methysergide—HTR2A—arteriole—atherosclerosis	0.0193	0.117	CbGeAlD
Methysergide—HTR7—vein—atherosclerosis	0.0185	0.112	CbGeAlD
Methysergide—Leg pain—Lovastatin—atherosclerosis	0.0145	0.0313	CcSEcCtD
Methysergide—HTR2A—vein—atherosclerosis	0.0115	0.0698	CbGeAlD
Methysergide—HTR1B—artery—atherosclerosis	0.00976	0.0591	CbGeAlD
Methysergide—Gastrointestinal symptom NOS—Niacin—atherosclerosis	0.00976	0.0211	CcSEcCtD
Methysergide—HTR1D—artery—atherosclerosis	0.00945	0.0572	CbGeAlD
Methysergide—Heartburn—Niacin—atherosclerosis	0.00834	0.018	CcSEcCtD
Methysergide—Heartburn—Pravastatin—atherosclerosis	0.00821	0.0177	CcSEcCtD
Methysergide—HTR2A—hindlimb—atherosclerosis	0.00766	0.0464	CbGeAlD
Methysergide—HTR1B—blood vessel—atherosclerosis	0.0076	0.0461	CbGeAlD
Methysergide—HTR7—artery—atherosclerosis	0.00753	0.0456	CbGeAlD
Methysergide—HTR1D—blood vessel—atherosclerosis	0.00736	0.0446	CbGeAlD
Methysergide—HTR2A—appendage—atherosclerosis	0.00657	0.0398	CbGeAlD
Methysergide—HTR7—endothelium—atherosclerosis	0.00636	0.0385	CbGeAlD
Methysergide—HTR7—blood vessel—atherosclerosis	0.00586	0.0355	CbGeAlD
Methysergide—Urine output increased—Niacin—atherosclerosis	0.00519	0.0112	CcSEcCtD
Methysergide—Pain in extremity—Lovastatin—atherosclerosis	0.00485	0.0105	CcSEcCtD
Methysergide—Pain in extremity—Ezetimibe—atherosclerosis	0.00476	0.0103	CcSEcCtD
Methysergide—Polyuria—Niacin—atherosclerosis	0.00474	0.0103	CcSEcCtD
Methysergide—HTR2A—artery—atherosclerosis	0.00469	0.0284	CbGeAlD
Methysergide—Eosinophilia—Lovastatin—atherosclerosis	0.00415	0.00897	CcSEcCtD
Methysergide—Eosinophilia—Ezetimibe—atherosclerosis	0.00407	0.0088	CcSEcCtD
Methysergide—HTR2A—endothelium—atherosclerosis	0.00397	0.024	CbGeAlD
Methysergide—Eosinophilia—Simvastatin—atherosclerosis	0.00388	0.00839	CcSEcCtD
Methysergide—Orthostatic hypotension—Niacin—atherosclerosis	0.0038	0.00822	CcSEcCtD
Methysergide—HTR1D—connective tissue—atherosclerosis	0.00377	0.0229	CbGeAlD
Methysergide—HTR2A—blood vessel—atherosclerosis	0.00366	0.0222	CbGeAlD
Methysergide—Eosinophilia—Pravastatin—atherosclerosis	0.00351	0.00759	CcSEcCtD
Methysergide—HTR1B—cardiovascular system—atherosclerosis	0.00339	0.0205	CbGeAlD
Methysergide—Dysuria—Pravastatin—atherosclerosis	0.00331	0.00716	CcSEcCtD
Methysergide—HTR1D—cardiovascular system—atherosclerosis	0.00328	0.0199	CbGeAlD
Methysergide—Oedema peripheral—Ezetimibe—atherosclerosis	0.00324	0.00701	CcSEcCtD
Methysergide—Weight increased—Pravastatin—atherosclerosis	0.00323	0.00697	CcSEcCtD
Methysergide—Weight decreased—Pravastatin—atherosclerosis	0.00321	0.00693	CcSEcCtD
Methysergide—Flushing—Lovastatin—atherosclerosis	0.00311	0.00673	CcSEcCtD
Methysergide—HTR2B—cardiovascular system—atherosclerosis	0.00305	0.0185	CbGeAlD
Methysergide—Flushing—Ezetimibe—atherosclerosis	0.00305	0.0066	CcSEcCtD
Methysergide—HTR7—connective tissue—atherosclerosis	0.00301	0.0182	CbGeAlD
Methysergide—Alopecia—Lovastatin—atherosclerosis	0.00296	0.00641	CcSEcCtD
Methysergide—Arthralgia—Rosuvastatin—atherosclerosis	0.00293	0.00634	CcSEcCtD
Methysergide—Myalgia—Rosuvastatin—atherosclerosis	0.00293	0.00634	CcSEcCtD
Methysergide—Flushing—Simvastatin—atherosclerosis	0.00291	0.0063	CcSEcCtD
Methysergide—Alopecia—Ezetimibe—atherosclerosis	0.00291	0.00629	CcSEcCtD
Methysergide—Oedema peripheral—Niacin—atherosclerosis	0.00284	0.00614	CcSEcCtD
Methysergide—Back pain—Lovastatin—atherosclerosis	0.00282	0.00611	CcSEcCtD
Methysergide—Alopecia—Simvastatin—atherosclerosis	0.00277	0.00599	CcSEcCtD
Methysergide—Back pain—Ezetimibe—atherosclerosis	0.00277	0.00599	CcSEcCtD
Methysergide—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00275	0.00595	CcSEcCtD
Methysergide—HTR1A—cardiovascular system—atherosclerosis	0.00274	0.0166	CbGeAlD
Methysergide—Ill-defined disorder—Lovastatin—atherosclerosis	0.00271	0.00586	CcSEcCtD
Methysergide—SIGMAR1—adipose tissue—atherosclerosis	0.0027	0.0164	CbGeAlD
Methysergide—HTR2B—adipose tissue—atherosclerosis	0.00269	0.0163	CbGeAlD
Methysergide—Flushing—Niacin—atherosclerosis	0.00267	0.00578	CcSEcCtD
Methysergide—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00266	0.00575	CcSEcCtD
Methysergide—Malaise—Lovastatin—atherosclerosis	0.00263	0.00569	CcSEcCtD
Methysergide—Flushing—Pravastatin—atherosclerosis	0.00263	0.00569	CcSEcCtD
Methysergide—HTR7—cardiovascular system—atherosclerosis	0.00262	0.0158	CbGeAlD
Methysergide—Malaise—Ezetimibe—atherosclerosis	0.00258	0.00558	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00256	0.00554	CcSEcCtD
Methysergide—Alopecia—Niacin—atherosclerosis	0.00255	0.0055	CcSEcCtD
Methysergide—Insomnia—Rosuvastatin—atherosclerosis	0.00254	0.0055	CcSEcCtD
Methysergide—Ill-defined disorder—Simvastatin—atherosclerosis	0.00253	0.00548	CcSEcCtD
Methysergide—Paraesthesia—Rosuvastatin—atherosclerosis	0.00253	0.00546	CcSEcCtD
Methysergide—Alopecia—Pravastatin—atherosclerosis	0.00251	0.00542	CcSEcCtD
Methysergide—Myalgia—Lovastatin—atherosclerosis	0.00249	0.00537	CcSEcCtD
Methysergide—Arthralgia—Lovastatin—atherosclerosis	0.00249	0.00537	CcSEcCtD
Methysergide—Chest pain—Lovastatin—atherosclerosis	0.00249	0.00537	CcSEcCtD
Methysergide—Dyspepsia—Rosuvastatin—atherosclerosis	0.00248	0.00535	CcSEcCtD
Methysergide—Malaise—Simvastatin—atherosclerosis	0.00246	0.00532	CcSEcCtD
Methysergide—Discomfort—Lovastatin—atherosclerosis	0.00246	0.00531	CcSEcCtD
Methysergide—Arthralgia—Ezetimibe—atherosclerosis	0.00244	0.00527	CcSEcCtD
Methysergide—Chest pain—Ezetimibe—atherosclerosis	0.00244	0.00527	CcSEcCtD
Methysergide—Myalgia—Ezetimibe—atherosclerosis	0.00244	0.00527	CcSEcCtD
Methysergide—Discomfort—Ezetimibe—atherosclerosis	0.00241	0.00521	CcSEcCtD
Methysergide—Pain—Rosuvastatin—atherosclerosis	0.0024	0.0052	CcSEcCtD
Methysergide—Constipation—Rosuvastatin—atherosclerosis	0.0024	0.0052	CcSEcCtD
Methysergide—Thrombocytopenia—Lovastatin—atherosclerosis	0.00233	0.00504	CcSEcCtD
Methysergide—Chest pain—Simvastatin—atherosclerosis	0.00233	0.00503	CcSEcCtD
Methysergide—Arthralgia—Simvastatin—atherosclerosis	0.00233	0.00503	CcSEcCtD
Methysergide—Myalgia—Simvastatin—atherosclerosis	0.00233	0.00503	CcSEcCtD
Methysergide—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00232	0.00501	CcSEcCtD
Methysergide—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.0023	0.00497	CcSEcCtD
Methysergide—Discomfort—Simvastatin—atherosclerosis	0.0023	0.00497	CcSEcCtD
Methysergide—Ill-defined disorder—Pravastatin—atherosclerosis	0.00229	0.00495	CcSEcCtD
Methysergide—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00229	0.00495	CcSEcCtD
Methysergide—Oedema—Simvastatin—atherosclerosis	0.00223	0.00482	CcSEcCtD
Methysergide—Malaise—Pravastatin—atherosclerosis	0.00223	0.00481	CcSEcCtD
Methysergide—Abdominal pain—Rosuvastatin—atherosclerosis	0.00222	0.00481	CcSEcCtD
Methysergide—Thrombocytopenia—Simvastatin—atherosclerosis	0.00218	0.00472	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00217	0.00469	CcSEcCtD
Methysergide—Insomnia—Lovastatin—atherosclerosis	0.00216	0.00466	CcSEcCtD
Methysergide—Paraesthesia—Lovastatin—atherosclerosis	0.00214	0.00463	CcSEcCtD
Methysergide—Arthralgia—Niacin—atherosclerosis	0.00214	0.00462	CcSEcCtD
Methysergide—Myalgia—Niacin—atherosclerosis	0.00214	0.00462	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00213	0.0046	CcSEcCtD
Methysergide—Dyspnoea—Lovastatin—atherosclerosis	0.00212	0.00459	CcSEcCtD
Methysergide—Insomnia—Ezetimibe—atherosclerosis	0.00211	0.00457	CcSEcCtD
Methysergide—Myalgia—Pravastatin—atherosclerosis	0.0021	0.00454	CcSEcCtD
Methysergide—Chest pain—Pravastatin—atherosclerosis	0.0021	0.00454	CcSEcCtD
Methysergide—Arthralgia—Pravastatin—atherosclerosis	0.0021	0.00454	CcSEcCtD
Methysergide—Paraesthesia—Ezetimibe—atherosclerosis	0.0021	0.00454	CcSEcCtD
Methysergide—Dyspepsia—Lovastatin—atherosclerosis	0.0021	0.00454	CcSEcCtD
Methysergide—Dyspnoea—Ezetimibe—atherosclerosis	0.00208	0.00451	CcSEcCtD
Methysergide—Discomfort—Pravastatin—atherosclerosis	0.00208	0.00449	CcSEcCtD
Methysergide—Dyspepsia—Ezetimibe—atherosclerosis	0.00206	0.00445	CcSEcCtD
Methysergide—Fatigue—Lovastatin—atherosclerosis	0.00205	0.00444	CcSEcCtD
Methysergide—Oedema—Niacin—atherosclerosis	0.00205	0.00443	CcSEcCtD
Methysergide—Pain—Lovastatin—atherosclerosis	0.00204	0.00441	CcSEcCtD
Methysergide—Constipation—Lovastatin—atherosclerosis	0.00204	0.00441	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00203	0.00439	CcSEcCtD
Methysergide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00202	0.00436	CcSEcCtD
Methysergide—Asthenia—Rosuvastatin—atherosclerosis	0.00202	0.00436	CcSEcCtD
Methysergide—Insomnia—Simvastatin—atherosclerosis	0.00202	0.00436	CcSEcCtD
Methysergide—Oedema—Pravastatin—atherosclerosis	0.00202	0.00436	CcSEcCtD
Methysergide—Fatigue—Ezetimibe—atherosclerosis	0.00202	0.00436	CcSEcCtD
Methysergide—Paraesthesia—Simvastatin—atherosclerosis	0.002	0.00433	CcSEcCtD
Methysergide—Constipation—Ezetimibe—atherosclerosis	0.002	0.00432	CcSEcCtD
Methysergide—Pain—Ezetimibe—atherosclerosis	0.002	0.00432	CcSEcCtD
Methysergide—Tachycardia—Niacin—atherosclerosis	0.002	0.00432	CcSEcCtD
Methysergide—Dyspnoea—Simvastatin—atherosclerosis	0.00199	0.0043	CcSEcCtD
Methysergide—Thrombocytopenia—Pravastatin—atherosclerosis	0.00197	0.00427	CcSEcCtD
Methysergide—Feeling abnormal—Lovastatin—atherosclerosis	0.00196	0.00425	CcSEcCtD
Methysergide—Dyspepsia—Simvastatin—atherosclerosis	0.00196	0.00424	CcSEcCtD
Methysergide—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00195	0.00421	CcSEcCtD
Methysergide—Feeling abnormal—Ezetimibe—atherosclerosis	0.00193	0.00416	CcSEcCtD
Methysergide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00192	0.00416	CcSEcCtD
Methysergide—Diarrhoea—Rosuvastatin—atherosclerosis	0.00192	0.00416	CcSEcCtD
Methysergide—Fatigue—Simvastatin—atherosclerosis	0.00192	0.00415	CcSEcCtD
Methysergide—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00191	0.00413	CcSEcCtD
Methysergide—Constipation—Simvastatin—atherosclerosis	0.00191	0.00412	CcSEcCtD
Methysergide—Pain—Simvastatin—atherosclerosis	0.00191	0.00412	CcSEcCtD
Methysergide—SIGMAR1—liver—atherosclerosis	0.00189	0.0115	CbGeAlD
Methysergide—Abdominal pain—Lovastatin—atherosclerosis	0.00188	0.00407	CcSEcCtD
Methysergide—Body temperature increased—Lovastatin—atherosclerosis	0.00188	0.00407	CcSEcCtD
Methysergide—HTR2A—connective tissue—atherosclerosis	0.00187	0.0114	CbGeAlD
Methysergide—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00186	0.00403	CcSEcCtD
Methysergide—Dizziness—Rosuvastatin—atherosclerosis	0.00186	0.00402	CcSEcCtD
Methysergide—Insomnia—Niacin—atherosclerosis	0.00185	0.004	CcSEcCtD
Methysergide—Body temperature increased—Ezetimibe—atherosclerosis	0.00185	0.00399	CcSEcCtD
Methysergide—Abdominal pain—Ezetimibe—atherosclerosis	0.00185	0.00399	CcSEcCtD
Methysergide—Paraesthesia—Niacin—atherosclerosis	0.00184	0.00397	CcSEcCtD
Methysergide—Feeling abnormal—Simvastatin—atherosclerosis	0.00184	0.00397	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00184	0.00397	CcSEcCtD
Methysergide—Dyspnoea—Niacin—atherosclerosis	0.00182	0.00395	CcSEcCtD
Methysergide—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00182	0.00394	CcSEcCtD
Methysergide—Insomnia—Pravastatin—atherosclerosis	0.00182	0.00394	CcSEcCtD
Methysergide—Somnolence—Niacin—atherosclerosis	0.00182	0.00393	CcSEcCtD
Methysergide—Paraesthesia—Pravastatin—atherosclerosis	0.00181	0.00391	CcSEcCtD
Methysergide—Dyspepsia—Niacin—atherosclerosis	0.0018	0.0039	CcSEcCtD
Methysergide—Dyspnoea—Pravastatin—atherosclerosis	0.0018	0.00388	CcSEcCtD
Methysergide—Dyspepsia—Pravastatin—atherosclerosis	0.00177	0.00384	CcSEcCtD
Methysergide—Rash—Rosuvastatin—atherosclerosis	0.00177	0.00383	CcSEcCtD
Methysergide—Dermatitis—Rosuvastatin—atherosclerosis	0.00177	0.00383	CcSEcCtD
Methysergide—Gastrointestinal disorder—Niacin—atherosclerosis	0.00177	0.00382	CcSEcCtD
Methysergide—Abdominal pain—Simvastatin—atherosclerosis	0.00176	0.00381	CcSEcCtD
Methysergide—Body temperature increased—Simvastatin—atherosclerosis	0.00176	0.00381	CcSEcCtD
Methysergide—Pain—Niacin—atherosclerosis	0.00175	0.00378	CcSEcCtD
Methysergide—Fatigue—Pravastatin—atherosclerosis	0.00174	0.00376	CcSEcCtD
Methysergide—Pain—Pravastatin—atherosclerosis	0.00172	0.00373	CcSEcCtD
Methysergide—Constipation—Pravastatin—atherosclerosis	0.00172	0.00373	CcSEcCtD
Methysergide—Asthenia—Lovastatin—atherosclerosis	0.00171	0.0037	CcSEcCtD
Methysergide—Asthenia—Ezetimibe—atherosclerosis	0.00168	0.00363	CcSEcCtD
Methysergide—Gastrointestinal pain—Niacin—atherosclerosis	0.00167	0.00362	CcSEcCtD
Methysergide—Nausea—Rosuvastatin—atherosclerosis	0.00167	0.00361	CcSEcCtD
Methysergide—Feeling abnormal—Pravastatin—atherosclerosis	0.00166	0.00359	CcSEcCtD
Methysergide—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00165	0.00356	CcSEcCtD
Methysergide—HTR2A—cardiovascular system—atherosclerosis	0.00163	0.00988	CbGeAlD
Methysergide—Diarrhoea—Lovastatin—atherosclerosis	0.00163	0.00353	CcSEcCtD
Methysergide—Abdominal pain—Niacin—atherosclerosis	0.00162	0.0035	CcSEcCtD
Methysergide—Body temperature increased—Niacin—atherosclerosis	0.00162	0.0035	CcSEcCtD
Methysergide—HTR7—liver—atherosclerosis	0.00162	0.0098	CbGeAlD
Methysergide—Asthenia—Simvastatin—atherosclerosis	0.0016	0.00346	CcSEcCtD
Methysergide—Diarrhoea—Ezetimibe—atherosclerosis	0.0016	0.00346	CcSEcCtD
Methysergide—Body temperature increased—Pravastatin—atherosclerosis	0.00159	0.00344	CcSEcCtD
Methysergide—Abdominal pain—Pravastatin—atherosclerosis	0.00159	0.00344	CcSEcCtD
Methysergide—Dizziness—Lovastatin—atherosclerosis	0.00158	0.00341	CcSEcCtD
Methysergide—Dizziness—Ezetimibe—atherosclerosis	0.00155	0.00334	CcSEcCtD
Methysergide—Diarrhoea—Simvastatin—atherosclerosis	0.00153	0.0033	CcSEcCtD
Methysergide—Vomiting—Lovastatin—atherosclerosis	0.00152	0.00328	CcSEcCtD
Methysergide—Rash—Lovastatin—atherosclerosis	0.0015	0.00325	CcSEcCtD
Methysergide—Dermatitis—Lovastatin—atherosclerosis	0.0015	0.00325	CcSEcCtD
Methysergide—Vomiting—Ezetimibe—atherosclerosis	0.00149	0.00321	CcSEcCtD
Methysergide—Dizziness—Simvastatin—atherosclerosis	0.00147	0.00319	CcSEcCtD
Methysergide—Rash—Ezetimibe—atherosclerosis	0.00147	0.00319	CcSEcCtD
Methysergide—Dermatitis—Ezetimibe—atherosclerosis	0.00147	0.00318	CcSEcCtD
Methysergide—Asthenia—Niacin—atherosclerosis	0.00147	0.00317	CcSEcCtD
Methysergide—Asthenia—Pravastatin—atherosclerosis	0.00145	0.00313	CcSEcCtD
Methysergide—Vomiting—Simvastatin—atherosclerosis	0.00142	0.00306	CcSEcCtD
Methysergide—Nausea—Lovastatin—atherosclerosis	0.00142	0.00306	CcSEcCtD
Methysergide—Rash—Simvastatin—atherosclerosis	0.00141	0.00304	CcSEcCtD
Methysergide—Dermatitis—Simvastatin—atherosclerosis	0.0014	0.00304	CcSEcCtD
Methysergide—Diarrhoea—Niacin—atherosclerosis	0.0014	0.00303	CcSEcCtD
Methysergide—Nausea—Ezetimibe—atherosclerosis	0.00139	0.003	CcSEcCtD
Methysergide—Diarrhoea—Pravastatin—atherosclerosis	0.00138	0.00298	CcSEcCtD
Methysergide—Dizziness—Niacin—atherosclerosis	0.00135	0.00293	CcSEcCtD
Methysergide—Dizziness—Pravastatin—atherosclerosis	0.00133	0.00288	CcSEcCtD
Methysergide—Nausea—Simvastatin—atherosclerosis	0.00132	0.00286	CcSEcCtD
Methysergide—Vomiting—Niacin—atherosclerosis	0.0013	0.00281	CcSEcCtD
Methysergide—Rash—Niacin—atherosclerosis	0.00129	0.00279	CcSEcCtD
Methysergide—Dermatitis—Niacin—atherosclerosis	0.00129	0.00279	CcSEcCtD
Methysergide—Vomiting—Pravastatin—atherosclerosis	0.00128	0.00277	CcSEcCtD
Methysergide—Rash—Pravastatin—atherosclerosis	0.00127	0.00275	CcSEcCtD
Methysergide—Dermatitis—Pravastatin—atherosclerosis	0.00127	0.00274	CcSEcCtD
Methysergide—Nausea—Niacin—atherosclerosis	0.00122	0.00263	CcSEcCtD
Methysergide—Nausea—Pravastatin—atherosclerosis	0.0012	0.00259	CcSEcCtD
Methysergide—HTR2A—liver—atherosclerosis	0.00101	0.00611	CbGeAlD
Methysergide—HTR1D—Signaling Pathways—ESR1—atherosclerosis	4.29e-05	0.000115	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—F2—atherosclerosis	4.27e-05	0.000115	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—F2—atherosclerosis	4.27e-05	0.000115	CbGpPWpGaD
Methysergide—HTR1E—GPCR downstream signaling—AKT1—atherosclerosis	4.26e-05	0.000114	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—F2—atherosclerosis	4.24e-05	0.000114	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KNG1—atherosclerosis	4.23e-05	0.000113	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—MMP9—atherosclerosis	4.22e-05	0.000113	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AGT—atherosclerosis	4.22e-05	0.000113	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—ESR1—atherosclerosis	4.2e-05	0.000113	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AGTR1—atherosclerosis	4.2e-05	0.000113	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—IL6—atherosclerosis	4.19e-05	0.000113	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—APOB—atherosclerosis	4.19e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—NFKB1—atherosclerosis	4.18e-05	0.000112	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—APOB—atherosclerosis	4.17e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—CXCL8—atherosclerosis	4.15e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—F2—atherosclerosis	4.15e-05	0.000111	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—APOE—atherosclerosis	4.13e-05	0.000111	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—LEP—atherosclerosis	4.13e-05	0.000111	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—CXCL8—atherosclerosis	4.13e-05	0.000111	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EDN1—atherosclerosis	4.12e-05	0.000111	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CCL2—atherosclerosis	4.12e-05	0.000111	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—MAPK8—atherosclerosis	4.11e-05	0.00011	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EDN1—atherosclerosis	4.1e-05	0.00011	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—AKT1—atherosclerosis	4.1e-05	0.00011	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CAV1—atherosclerosis	4.1e-05	0.00011	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PLG—atherosclerosis	4.09e-05	0.00011	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCL5—atherosclerosis	4.09e-05	0.00011	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CG—atherosclerosis	4.09e-05	0.00011	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—APOA1—atherosclerosis	4.09e-05	0.00011	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CG—atherosclerosis	4.08e-05	0.00011	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCL5—atherosclerosis	4.07e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CG—atherosclerosis	4.06e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—LPL—atherosclerosis	4e-05	0.000107	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MMP9—atherosclerosis	3.98e-05	0.000107	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—LPL—atherosclerosis	3.98e-05	0.000107	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CG—atherosclerosis	3.97e-05	0.000107	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—ESR1—atherosclerosis	3.95e-05	0.000106	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—NFKB1—atherosclerosis	3.94e-05	0.000106	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—MAPK3—atherosclerosis	3.91e-05	0.000105	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—MAPK3—atherosclerosis	3.91e-05	0.000105	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—F2—atherosclerosis	3.9e-05	0.000105	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PRKCG—atherosclerosis	3.89e-05	0.000104	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—MAPK3—atherosclerosis	3.88e-05	0.000104	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SOCS3—atherosclerosis	3.88e-05	0.000104	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MAPK8—atherosclerosis	3.88e-05	0.000104	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—INS—atherosclerosis	3.87e-05	0.000104	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PRKCG—atherosclerosis	3.87e-05	0.000104	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—AKT1—atherosclerosis	3.86e-05	0.000104	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—INS—atherosclerosis	3.86e-05	0.000104	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—INS—atherosclerosis	3.84e-05	0.000103	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCL2—atherosclerosis	3.81e-05	0.000102	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—MAPK3—atherosclerosis	3.8e-05	0.000102	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCL2—atherosclerosis	3.8e-05	0.000102	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—VEGFA—atherosclerosis	3.79e-05	0.000102	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SPP1—atherosclerosis	3.79e-05	0.000102	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCL2—atherosclerosis	3.78e-05	0.000101	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—CXCL8—atherosclerosis	3.77e-05	0.000101	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SPP1—atherosclerosis	3.77e-05	0.000101	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—INS—atherosclerosis	3.76e-05	0.000101	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—STAT3—atherosclerosis	3.76e-05	0.000101	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—CXCL8—atherosclerosis	3.75e-05	0.000101	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP3—atherosclerosis	3.74e-05	0.000101	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IGF1—atherosclerosis	3.74e-05	0.0001	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IGF1—atherosclerosis	3.74e-05	0.0001	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CG—atherosclerosis	3.73e-05	0.0001	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF2—atherosclerosis	3.73e-05	0.0001	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IGF1—atherosclerosis	3.71e-05	9.97e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCL2—atherosclerosis	3.7e-05	9.93e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IGF1—atherosclerosis	3.64e-05	9.77e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APOB—atherosclerosis	3.62e-05	9.72e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—MAPK3—atherosclerosis	3.59e-05	9.64e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—CXCL8—atherosclerosis	3.59e-05	9.63e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—VEGFA—atherosclerosis	3.58e-05	9.61e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—MAPK3—atherosclerosis	3.57e-05	9.6e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EDN1—atherosclerosis	3.56e-05	9.56e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SERPINE1—atherosclerosis	3.55e-05	9.54e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SERPINE1—atherosclerosis	3.55e-05	9.53e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—STAT3—atherosclerosis	3.54e-05	9.52e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCL5—atherosclerosis	3.53e-05	9.49e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—INS—atherosclerosis	3.53e-05	9.48e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SERPINE1—atherosclerosis	3.53e-05	9.47e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	3.5e-05	9.41e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PDGFB—atherosclerosis	3.49e-05	9.36e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TGFB1—atherosclerosis	3.48e-05	9.35e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCL2—atherosclerosis	3.47e-05	9.33e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—LPL—atherosclerosis	3.45e-05	9.28e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	3.45e-05	9.27e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AGT—atherosclerosis	3.42e-05	9.19e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IGF1—atherosclerosis	3.42e-05	9.17e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AGT—atherosclerosis	3.4e-05	9.14e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NOS3—atherosclerosis	3.39e-05	9.11e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NOS3—atherosclerosis	3.39e-05	9.1e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MAPK3—atherosclerosis	3.38e-05	9.09e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NOS3—atherosclerosis	3.37e-05	9.04e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	3.36e-05	9.02e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—APOE—atherosclerosis	3.35e-05	9e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—LEP—atherosclerosis	3.35e-05	9e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—APOE—atherosclerosis	3.33e-05	8.96e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—LEP—atherosclerosis	3.33e-05	8.96e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CAV1—atherosclerosis	3.32e-05	8.92e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—APOA1—atherosclerosis	3.31e-05	8.9e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CAV1—atherosclerosis	3.3e-05	8.87e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NOS3—atherosclerosis	3.3e-05	8.85e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—APOA1—atherosclerosis	3.3e-05	8.85e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TGFB1—atherosclerosis	3.28e-05	8.82e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SPP1—atherosclerosis	3.27e-05	8.79e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	3.26e-05	8.75e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SERPINE1—atherosclerosis	3.24e-05	8.71e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—ESR1—atherosclerosis	3.2e-05	8.6e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—ESR1—atherosclerosis	3.18e-05	8.55e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—F2—atherosclerosis	3.16e-05	8.49e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—F2—atherosclerosis	3.14e-05	8.45e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NOS3—atherosclerosis	3.1e-05	8.32e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	3.03e-05	8.13e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	3.03e-05	8.13e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	3.01e-05	8.08e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CXCL8—atherosclerosis	3.01e-05	8.08e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CXCL8—atherosclerosis	3.01e-05	8.07e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	2.99e-05	8.02e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AGT—atherosclerosis	2.96e-05	7.94e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	2.92e-05	7.85e-05	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—AKT1—atherosclerosis	2.91e-05	7.81e-05	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—AKT1—atherosclerosis	2.9e-05	7.8e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	2.9e-05	7.78e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APOE—atherosclerosis	2.9e-05	7.78e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—LEP—atherosclerosis	2.9e-05	7.78e-05	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	2.89e-05	7.75e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	2.88e-05	7.74e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CAV1—atherosclerosis	2.87e-05	7.71e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—INS—atherosclerosis	2.86e-05	7.69e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APOA1—atherosclerosis	2.86e-05	7.69e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—IL6—atherosclerosis	2.86e-05	7.69e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—IL6—atherosclerosis	2.86e-05	7.68e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—INS—atherosclerosis	2.85e-05	7.65e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL6—atherosclerosis	2.84e-05	7.63e-05	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	2.82e-05	7.59e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCL2—atherosclerosis	2.82e-05	7.57e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCL2—atherosclerosis	2.8e-05	7.53e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—atherosclerosis	2.78e-05	7.47e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IGF1—atherosclerosis	2.77e-05	7.44e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ESR1—atherosclerosis	2.76e-05	7.43e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IGF1—atherosclerosis	2.76e-05	7.4e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	2.75e-05	7.38e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—F2—atherosclerosis	2.73e-05	7.33e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—atherosclerosis	2.72e-05	7.31e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—atherosclerosis	2.72e-05	7.3e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—atherosclerosis	2.7e-05	7.25e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NFKB1—atherosclerosis	2.69e-05	7.23e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NFKB1—atherosclerosis	2.69e-05	7.22e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	2.67e-05	7.18e-05	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	2.65e-05	7.13e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MAPK8—atherosclerosis	2.65e-05	7.11e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—atherosclerosis	2.64e-05	7.1e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MAPK8—atherosclerosis	2.64e-05	7.1e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—atherosclerosis	2.64e-05	7.09e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—atherosclerosis	2.64e-05	7.08e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	2.63e-05	7.06e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	2.63e-05	7.06e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—atherosclerosis	2.62e-05	7.05e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	2.62e-05	7.04e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	2.62e-05	7.03e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	2.62e-05	7.03e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	2.61e-05	7.02e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—atherosclerosis	2.61e-05	7.02e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	2.57e-05	6.91e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	2.57e-05	6.89e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NOS3—atherosclerosis	2.51e-05	6.74e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	2.5e-05	6.72e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NOS3—atherosclerosis	2.5e-05	6.71e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—atherosclerosis	2.48e-05	6.67e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—atherosclerosis	2.47e-05	6.65e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—INS—atherosclerosis	2.47e-05	6.64e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	2.46e-05	6.6e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—atherosclerosis	2.44e-05	6.56e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—atherosclerosis	2.44e-05	6.56e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCL2—atherosclerosis	2.43e-05	6.54e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	2.43e-05	6.51e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—atherosclerosis	2.42e-05	6.5e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—atherosclerosis	2.42e-05	6.5e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—atherosclerosis	2.42e-05	6.49e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	2.42e-05	6.49e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	2.41e-05	6.47e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—atherosclerosis	2.4e-05	6.45e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF1—atherosclerosis	2.39e-05	6.43e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	2.38e-05	6.38e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—atherosclerosis	2.35e-05	6.32e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MAPK3—atherosclerosis	2.31e-05	6.21e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MAPK3—atherosclerosis	2.31e-05	6.2e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	2.29e-05	6.16e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—atherosclerosis	2.28e-05	6.13e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	2.27e-05	6.1e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	2.25e-05	6.03e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TGFB1—atherosclerosis	2.24e-05	6.03e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TGFB1—atherosclerosis	2.24e-05	6.02e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	2.23e-05	5.99e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	2.23e-05	5.98e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	2.23e-05	5.98e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	2.22e-05	5.95e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—atherosclerosis	2.21e-05	5.93e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	2.18e-05	5.85e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOS3—atherosclerosis	2.17e-05	5.83e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	2.15e-05	5.78e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	2.14e-05	5.75e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—atherosclerosis	2.12e-05	5.69e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	2.11e-05	5.67e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—atherosclerosis	2.11e-05	5.66e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	2.05e-05	5.5e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—atherosclerosis	2.01e-05	5.41e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—atherosclerosis	2e-05	5.38e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.99e-05	5.35e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	1.98e-05	5.33e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.96e-05	5.26e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.95e-05	5.25e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	1.95e-05	5.24e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	1.94e-05	5.22e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.92e-05	5.17e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.86e-05	4.99e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.83e-05	4.91e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.81e-05	4.86e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	1.8e-05	4.83e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.79e-05	4.81e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—atherosclerosis	1.78e-05	4.79e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—atherosclerosis	1.74e-05	4.67e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	1.72e-05	4.63e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	1.71e-05	4.6e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	1.7e-05	4.57e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	1.69e-05	4.55e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—atherosclerosis	1.69e-05	4.54e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—atherosclerosis	1.69e-05	4.54e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	1.69e-05	4.53e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—atherosclerosis	1.68e-05	4.51e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	1.66e-05	4.46e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	1.65e-05	4.44e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—atherosclerosis	1.64e-05	4.41e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.56e-05	4.2e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—atherosclerosis	1.56e-05	4.19e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—atherosclerosis	1.56e-05	4.18e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—atherosclerosis	1.55e-05	4.16e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.55e-05	4.16e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—atherosclerosis	1.54e-05	4.14e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—atherosclerosis	1.52e-05	4.07e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.48e-05	3.97e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.43e-05	3.85e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—atherosclerosis	1.42e-05	3.82e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.25e-05	3.36e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.24e-05	3.34e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.15e-05	3.1e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.15e-05	3.08e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.08e-05	2.9e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—atherosclerosis	9.97e-06	2.68e-05	CbGpPWpGaD
